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Abstract
Background: In response to tissue damage or inflammation, adenosine-5′-triphosphate (ATP) is released into the
extracellular compartment and has been demonstrated to augment inflammation via purinergic P2 receptors (P2Rs).
Recently, ATP has been shown to be increased in the airways of COPD patients. In the present study, we examined the
possible involvement of extracellular ATP in airway mucus hypersecretion during viral-induced COPD exacerbations.
Methods: The involvement of extracellular ATP in the release of a major airway mucin, MUC5AC, and its signal pathway
was examined after stimulation with polyinosine-polycytidylic acid [poly(I:C)], a synthetic analog of dsRNA to mimic viral
infection, and rhinovirus (RV) infection in NCI-H292 cells and differentiated airway epithelial cells from COPD patients.
Results: Treatment with poly(I:C) significantly increased the amount of extracellular ATP and induced MUC5AC release
in NCI-H292 cells. Pre-treatment with a pannexin channel inhibitor, carbenoxolone (CBX), reduced the amount of
extracellular ATP and suppressed MUC5AC release from poly(I:C)-treated cells. Pre-treatment with the P2R antagonist
suramin significantly reduced the expression and release of MUC5AC. The inhibitory effects of CBX and suramin on the
release of ATP and/or MUC5AC were replicated with RV infection. Pre-treatment with suramin also significantly reduced
the expression and amount of extracellular EGFR ligands and the phosphorylation of EGFR and ERK in poly(I:C)-treated
cells. In addition, pre-treatment with a P2Y2 receptor siRNA significantly suppressed the poly(I:C)-potentiated EGFR
ligands and MUC5AC release. After poly(I:C) stimulation, the expression of MUC5AC in the differentiated cells from
COPD patients was significantly higher than those from healthy subjects and the values of MUC5AC expression were
inversely related with forced expiratory volume in 1 s (FEV1) % predicted. The inhibitory effects of CBX and suramin on
poly(I:C)-potentiated MUC5AC expression were confirmed in differentiated airway epithelium from COPD patients.
Conclusions: These results demonstrate that dsRNA induces the release of ATP via pannexin channel and that the
extracellular ATP is involved in the expression and release of MUC5AC, mainly via P2Y2R, in an autocrine manner.
Modulation of this pathway could be a therapeutic target for viral-induced mucus hypersecretion in COPD exacerbations.
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Background
Chronic obstructive pulmonary disease (COPD) is a lead-
ing cause of morbidity and mortality throughout the world
[1]. Exacerbations of COPD, defined as worsening of the
symptoms including cough, sputum, and/or dyspnea, cause
an acute deterioration in airway inflammation and lung
function, and it also leads an acceleration of the rate of
decline of lung function and increasing the mortality [2, 3].
Therefore, preventing exacerbations of COPD is necessary.
However, the precise mechanisms by which exacerbations
occur have not been fully elucidated.
Adenosine-5′-triphosphate (ATP) is well known as an
energy source in the intracellular compartments. On the
other hand, once released into the extracellular compart-
ment in response to tissue damage or inflammation,
extracellular ATP has been shown to act as a potent
inducer of inflammation [4, 5]. Although ATP is known
to be released from necrotic cells [6], it has been
recently demonstrated to be released from intact cells
through pannexin channels [7–9]. Extracellular ATP acts
via purinergic P2 receptors (P2Rs) composed by seven
members of the P2X receptor (P2XR; P2X1R-P2X7R)
and eight members of the P2Y receptor (P2YR; P2Y1R,
P2Y2R, P2Y4R, P2Y6R, P2Y11R-P2Y14R); the former
are ligand-gated ion channels and the latter are G
protein-coupled receptors [4, 5]. Especially, P2X7R has
been shown to be involved in inflammation [10], and
P2Y2R reported to be involved in the release of mucin
from secretory glands [11, 12]. In the airway of COPD
patients, an increased concentration of extracellular ATP
has been demonstrated, especially during acute smoke
exposure [13], suggesting that extracellular ATP might
be involved in the pathophysiology of COPD and
exacerbations.
Mucus hypersecretion in the airway is a common
feature of this disease, especially during exacerbations.
Although mucin production is a component of the
innate immune defense mediated by airway epithelia,
mucus overproduction causes airway obstruction, which
may lead to COPD exacerbations [14–16]. Viral
infection, which is known as the primary cause of COPD
exacerbations, induces mucus secretion [17] and the
production of a major secreted mucin, MUC5AC [18].
Viral-induced immune reactions are mediated by
Toll-like receptors (TLRs), especially TLR3, through the
recognition of viral-derived double-stranded RNA
(dsRNA) [19, 20]. Recently, we and others have shown
that viral infection and the stimulation of TLR3 induces
the expression and production of MUC5AC in airway
epithelial cells mainly via epidermal growth factor
receptor (EGFR) and extracellular signal-regulated kinase
(ERK) signaling pathways [21, 22].
Viral infection and dsRNA have been shown to
increase the amount of extracellular ATP [23, 24] and
the production of mucin in airways via TLR3 [21, 22].
However, the involvement of extracellular ATP in
viral-induced mucin production in airway epithelial cells
remains unclear. In the present study, we evaluated the
following points, using NCI-H292 cells and differentiated
primary human bronchial epithelial cells (HBECs) from
normal subjects and COPD patients: (a) whether pannexin
channels are involved in ATP release, (b) whether the
inhibition of P2Rs, especially P2X7R and P2Y2R, affects
MUC5AC production and the EGFR-ERK signaling
pathway after stimulation with a synthetic dsRNA
analogue, polyinosinic-polycytidylic acid [poly(I:C)], as a




Poly(I:C) (polyinosinic acid/polycytidylic acid, sodium
salt, double-stranded) were purchased from Calbiochem
(La Jolla, CA). Carbenoxolone (CBX), suramin, Brilliant
Blue G (BBG) and A438079 were from Sigma-Aldrich
(St. Louis, MO).
Patients
Five control subjects including four never smokers and
one ex-smoker without COPD and five former smokers
with COPD took part in our study after giving written in-
formed consent (Table 1). COPD was diagnosed according
to the GOLD guidelines [1]. All subjects had undergone
surgery for lung cancer after receiving pulmonary function
tests. Human bronchial tissues were obtained from the
2-4 bronchi of the lobe resected at surgery, avoiding areas
involved by tumors. The tissues were used for the culture
of human bronchial cells. All experiments in the study
were approved by ethics committee of Tohoku University
Graduate School of Medicine.
Table 1 Clinical characteristics of patients
Healthy subjects (n = 5) COPD (n = 5)
Sex (Male/Female) 1/4 5/0
Age (years) 69.5 ± 6.06 70.6 ± 3.84
Ex-smoker 1 5
smoking history (pack-year) 8.0 ± 17.9 76.7 ± 73.7*
FVC (L) 2.82 ± 0.24 3.30 ± 0.38*
FVC % predicted 115 ± 12.3 96.0 ± 7.89*
FEV1 (L) 2.18 ± 0.15 2.14 ± 0.50
FEV1 % predicted 113 ± 19.2 74.3 ± 17.0*
FEV1/FVC (%) 77.5 ± 9.54 64.0 ± 10.2
DLCO/VA % predicted 102 ± 10.5 86.2 ± 8.62*
COPD chronic obstructive pulmonary disease; pack-year: 1 year smoking 20
cigarettes-day; FVC forced vital capacity; FEV1 forced expiratory volume in one
second; DLCO diffusing capacity of the lung for carbon monoxide; VA alveolar
volume. Values are mean ± SE. *p < 0.05 compared to healthy subjects
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Preparation of epithelial cells
NCI-H292 cells, a human pulmonary mucoepidermoid
carcinoma cell line (ATCC, Manassas, VA) were cultured
according to our previous study [22]. Cells were cultured
in RPMI-1640 medium supplemented with 10 % FBS at
37 °C in a humidified atmosphere of 5 % CO2. Cells were
grown to 80 % confluence in 24-well and maintained in
FBS-free medium for 24 h before stimulation. Primary
human bronchial epithelial cells (HBECs) obtained from
lobes resected from patients at surgery were used for the
air–liquid culture at passages 2–3. The air-liquid culture
of HBECs was conducted using Clonetics® B-ALITM
Air-Liquid Interface (ALI) according to our previous
study [22]. The ALI state was maintained for 7–10 days,
as previous studies have shown this duration is required
for mucociliary differentiation [25, 26].
To investigate the effect of poly(I:C) on the cells,
supernatants were harvested at 24 h after treatment with
poly(I:C) at the concentration of 10 μg/ml [22]. A
pannexin channel inhibitor, CBX, a non-selective P2R
antagonist, suramin, a non-selective P2X7 antagonist,
BBG and a selective P2X7 antagonist, A438079 were
added to the media at various concentrations 30–60 min
prior to poly(I:C)-treatment. To stimulate ALI state cells,
100 μl of media containing poly(I:C) was added on top of
cells at the apical side of differentiated epithelial cells.
Rhinovirus infection
A stock solution of type 14 rhinovirus (RV14) [1.0 × 107
tissue culture infectious dose (TCID50)/ ml] was prepared
from a patient with a common cold and the rate of RV14
release was titrated according to previously described
methods [27]. NCI-H292 cells cultured in 24-well plates
were infected with RV14 at a multiplicity of infection
(MOI) of 1 for 90 min in RPMI-1640 medium at 33 °C
before the virus was removed and replaced with RPMI-
1640 medium [18, 28]. In some experiments, cells were
pretreated with CBX or suramin 30–60 min prior to infec-
tion. After the cells were cultured for 24–48 h at 33 °C,
the supernatants were removed and stored at −80 °C until
required.
Measurement of ATP
To measure the amount of ATP in cell culture superna-
tants, samples were centrifuged at ice-cold at 14,000 rpm
for 2 min and the supernatants were stored at −80 °C
prior to analysis. The amount of ATP was measured using
ATP Assay Kit (BioVision Inc.; Milpitas, CA) according to
the manufacturer’s instructions.
ELISA
MUC5AC protein was measured by ELISA based
methods according to our previous study [21]. Amphire-
gulin and TGF-α were measured using ELISA (R&D
Systems, Inc.; Minneapolis, MN) according to the
manufacturer’s instructions.
Immunocytochemistry
Cells were seeded in 8-well chamber slides at a density
of 1 × 105/ml and cultured for 24 h, and then the
medium was replaced with FBS-free medium for a fur-
ther 24 h. After washing with PBS, the slides were fixed
with freshly prepared 4 % paraformaldehyde in PBS for
10 min at room temperature. The slides were perme-
abilized with 0.1 % Triron X-100 in PBS for 10 min at
room temperature. The slides were then blocked for
30 min at room temperature by 1 % skim milk, rinsed,
and then incubated overnight with mouse monoclonal
anti-MUC5AC (Clone 45 M1) antibody (1:50 dilution;
Thermo Fisher Scientific, Fremont, CA) at 4 °C. After
washing with PBS, the slides were incubated with goat
anti-mouse IgG conjugated with FITC (1:200 dilution;
Abcam, Cambridge, UK) for 1 h at room temperature.
After washing, the nuclei of the cells were stained with
Fluoromount-G containing DAPI (Southern Biotech,
Birmingham, AL). The slides were then viewed with a
multiphoton confocal LSM 780 NLO microscope system
(Carl Zeiss, Jena, Germany) under x400 magnification.
Immunoblotting
Cells were seeded in 6-well or 60 mm dishes at a density
of 1 × 105/ml. At 80 % confluence, cells were maintained
in FBS-free medium for 24 h before stimulation. To
evaluate the inhibitory effect of suramin on the
expression of phospho-EGFR (pEGFR) and phospho-
extracellular signal-regulated kinase (pERK), the cells
were treated with suramin 30 min prior to poly(I:C)-
stimulation. Four hours after poly(I:C)-stimulation, cells
were washed with ice-cold HANK’s balanced salt
solution (HBSS) and homogenized in cell lysis buffer
(0.05 % TritonX, 35 mM Tris-HCl, pH 7.4, 0.4 mM
EGTA, 10 mM MgCl2, 1 μM phenylmethylsulfonyl fluor-
ide, 100 μg/ml aprotinin and 1 μg/ml leupeptin) at 4 °C.
Samples were solubilized in SDS-PAGE sample buffer.
Equal amounts of protein were loaded and separated by
electrophoresis on 12.5 % SDS polyacrylamide gels. After
electrophoresis, separated proteins were transferred to a
PVDF membrane (Bio-Rad Laboratories, Herculer, CA).
Rabbit polyclonal anti-phospho-EGF receptor antibody
(1:1000 dilution), rabbit polyclonal anti-EGF receptor
antibody (1:5000), rabbit polyclonal anti-phospho-ERK1/
2 antibody (1:1000), rabbit polyclonal anti-ERK1/2 anti-
body (1:5000, all from Cell Signaling Technology, Danvers,
MA) were used to detect the target proteins. Appropriate
peroxidase-conjugated secondary antibodies were detected
using ECL-plus (Amersham Biosciences, Buckinghamshire,
UK) and visualized with a chemiluminescence imaging
system (LAS-4000 mini; Fujifilm, Tokyo, Japan). Each band
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intensity was quantified by densitometry (Quantity One
software, Bio-Rad, Hercules, CA, USA).
Real-time PCR
Total RNA was isolated from NCI-H292 cells and HBECs
differentiated in ALI to prepare cDNA using TaqMan
Gene Expression Cell-to-CTTM Kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s
instructions. cDNA was amplified with specific primers to
MUC5AC, TGF-α, amphiregulin, TLR3 and GAPDH using
the 7500 Real-Time PCR System (Applied Biosystems).
Primers used to amplify cDNA were from TaqMan Gene
Expression Assays (Biosystems): MUC5AC (catalogue
number Hs01365616_ml), TLR3 (Hs00152933_ml), TGF-α
(Hs00608187_ml), amphiregulin (Hs00950669_ml) and
GAPDH (Hs99999905_ml). Relative quantification of
different transcripts was determined with the comparative
threshold cycle (CT) method using GAPDH as the
endogenous control. Results were calculated as fold
induction over control.
Silencing of P2R
Cells were seeded in 6-well plates in complete media. At
50 % confluence, transfection with siRNA was performed.
In one tube, 9 μl of Lipofectamine RNAiMAX (Invitrogen
Life Technologies, Grand Island, NY) were mixed gently
with 150 μl Opti-MEM medium (Invitrogen Life
Technologies, Grand Island, NY). In a separate tube, 300
pmol of non-targeting, P2X7R or P2Y2R siRNA
(ON-TARGETplus SMARTpool; Dharmacon, Lafayette,
CO) were mixed gently with 150 μl Opti-MEM medium.
These siRNA and lipofectamine solutions were then
combined, gently mixed and incubated for 5 min at room
temperature. After incubation, the siRNA duplex-
lipofectamine complexes were added to each dish (final
concentration of siRNAs = 100 nM). Cells were incubated
at 37 °C for 6 h. Then, media were changed and further
cultured for 24 h. After that, media were changed to
serum-free medium and further cultured for 24 h. The
siRNA treated cells were then used to assess the role of
the P2X7R or P2Y2R on MUC5AC release in the presence




terazolium bromide (MTT; Sigma-Aldrich, St. Louis,
MO) was prepared using HBSS. Supernatants were
removed from cells, and MTT solution was added to
each well. After 1 h incubation at 37 °C, the MTT
solution was discarded and DMSO was added to each
well. The product was quantified at 570 nm with a
micro plate reader. To evaluate the cell viability in
ALI state cells, the lactate dehydrogenase (LDH)
activity was measured in the supernatants from the
cells using Cytotoxicity Detection KitPLUS (LDH)
(Sigma-Aldrich) according to the manufacturer’s
instructions.
Statistical Analysis
Data are expressed as the mean ± SEM. GraphPad Prism
(GraphPad Software Inc., SanDiego, CA) was used for
statistical test. Experiments with multiple comparisons
were evaluated using one way analysis of variance
(ANOVA) by Bonferroni’s test to adjust for multiple
comparisons. Mann-Whitney U test was used for single
comparison. Spearman’s correlation was also used to as-
sess statistical significance when applicable. Significance
was defined as p < 0.05.
Results
Involvement of extracellular ATP on MUC5AC release in
poly(I:C)-treated NCI-H292 cells
In our previous study, we confirmed that TLR3 was
expressed in NCI-H292 cells, a human pulmonary mucoe-
pidermoid carcinoma cell line, and a synthetic dsRNA
analogue, poly(I:C), used as a TLR3 ligand to mimic viral
infection, induced the expression and release of MUC5AC
from the cells [22]. Here, to determine the involvement of
extracellular ATP on MUC5AC release from airway
epithelial cells after TLR3 stimulation, we investigated the
amount of extracellular ATP in poly(I:C)-treated NCI-
H292 cells. Treatment with poly(I:C) significantly increased
the amount of extracellular ATP at 8 h or later at a
concentration of 10 μg/ml (3.12 ± 0.80 at 0 h vs 9.56 ±
1.38 μM at 8 h, p < 0.001), without affecting cell viability
(Fig. 1a and b). In the same way, poly(I:C)-potentiated
MUC5AC release was shown at 16 h or later (at 24 h, 2.48-
fold increase, p < 0.001) (Fig. 1c). Exogenous ATP alone also
increased the release of MUC5AC at 16 h or later at a con-
centration of 10 μM (at 24 h, 3.01-fold increase, p < 0.001)
(Fig. 1d). After 24 h stimulation with exogenous ATP, the
release of MUC5AC was dose-dependently increased at a
concentration of less than 10 μM (Fig. 1e) and the intracel-
lular production of MUC5AC was confirmed by immuno-
cytochemistry (Fig. 1f). Recently, cigarette smoke-bubbled
medium was reported to induce the release of ATP from
HBECs via pannexin channel [7], which suggested the pos-
sible involvement of pannexin channel in poly(I:C)-induced
ATP release. Therefore, we investigated the effect of pan-
nexin channel inhibitor, carbenoxolone (CBX) on the
release of ATP from NCI-H292 cells after poly(I:C)
stimulation. Pre-treatment with 10 μM CBX significantly
reduced the amount of extracellular ATP in poly(I:C)-
treated cells at 12 h and 24 h (at 12 h, 14.2 ± 0.29 vs 6.84 ±
0.21 μM, p < 0.001) (Fig. 1g). Pre-treatment of 10 μM CBX
also partially but significantly suppressed poly(I:C)-induced
MUC5AC release from NCI-H292 cells (p < 0.01) (Fig. 1h).
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Effect of P2R inhibition on MUC5AC production and
release in poly(I:C)-treated NCI-H292 cells
To investigate the effect of P2R antagonist on poly(I:C)-in-
duced MUC5AC release in NCI-H292 cells, we used a
non-selective antagonist of P2R, suramin. Suramin
significantly inhibited the expression and production of
poly(I:C)-potentiated MUC5AC at 10 μM (Fig. 2a, b) and
also decreased the release of poly(I:C)-potentiated
MUC5AC at the concentrations of 1 to 100 μM (p < 0.001)





Fig. 1 Involvement of extracellular ATP in MUC5AC release in poly(I:C)-treated NCI-H292 cells. a-c Effect of poly(I:C) on cell viability and the release of
extracellular ATP and MUC5AC from NCI-H292 cells. Cells were treated with 10 μg/ml poly(I:C). At various time points after the incubation, whole cells and
supernatants were harvested and assayed. a Supernatants were assessed for the concentration of extracellular ATP by fluorometric assay. b Cell viability
was assessed by MTT assay. Cell viability was calculated as the percentage of viable cells among poly(I:C)-treated cells at 0 min. c Supernatants were
assayed for MUC5AC release by ELISA. (D-E) Release of MUC5AC in ATP-treated cells. d Cells were treated with 10 μM ATP. At various time points after the
incubation, the supernatants were harvested and assayed. e Cells were treated with various concentrations of ATP. After 24 h, the supernatants were
harvested and assayed for MUC5AC release. f Panels show representative photographs of the immunoreactivity of MUC5AC in NCI-H292 cells. Treatment
with 10 μM ATP augmented the immunoreactivity of MUC5AC. Original magnification: x200. g, h Effect of a pannexin channel inhibitor, carbenoxolone
(CBX), on the release of extracellular ATP and MUC5AC in poly(I:C)-treated cells. g Cells were treated with 10 μM CBX or vehicle 1 h prior to the treatment
with 10 μg/ml poly(I:C). At various points after incubation, the supernatants were harvested and assessed for the concentration of extracellular ATP.
h Various concentrations of CBX were added 1 h before 10 μg/ml poly(I:C) treatment. After 24 h, the supernatants were harvested and assayed for
MUC5AC release. The data are expressed as the means ± SEM for three to six separate experiments. *p< 0.05, **p< 0.01, ***p< 0.001 compared with the
values of vehicle-treated control. +++p< 0.001 compared with the values of poly(I:C)-treated control
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in poly(I:C)-potentiated MUC5AC release via extracellular
ATP, we first used P2X7R antagonists because P2X7R was
recently implicated in the augmentation of various media-
tors after stimulation of TLRs [10]. A non-selective P2X7R
antagonist, Brilliant Blue G (BBG), significantly inhibited
poly(I:C)-potentiated MUC5AC release at 50 and 100 μM
(p < 0.001) (Fig. 2d), but a specific P2X7R antagonist,
A438079, did not at concentrations up to 100 μM (Fig. 2e).
To account for this discrepancy, the effect of P2X7R
silencing on poly(I:C)-induced MUC5AC release was
evaluated. Although treatment with siRNA decreased
the P2X7R protein, P2X7R knockdown did not affect
poly(I:C)-augmented MUC5AC release (p < 0.05) (Fig. 3a
and b). Next, we examined the involvement of P2Y2R
in poly(I:C)-potentiated MUC5AC release because
P2Y2R stimulation induced mucin release from
secretory glands [11, 12]. Since there is no available
selective inhibitor for P2Y2R, siRNA for P2Y2R was
used to estimate the inhibitory effect on the release of
MUC5AC. Treatment with P2Y2R siRNA suppressed
P2Y2R protein expression (p < 0.05) (Fig. 3c) and sig-
nificantly inhibited the poly(I:C)-potentiated MUC5AC
release (p < 0.001) (Fig. 3d).
Effect of P2R inhibition on EGFR ligand expression and
release in poly(I:C)-treated NCI-H292 cells
The EGFR-ERK signaling pathways were reported to
be involved in poly(I:C)-induced MUC5AC expression
and release [21, 22]. To clarify whether P2R is in-
volved in poly(I:C)-potentiated EGFR ligands, we in-
vestigate the effect of P2R antagonist and P2Y2R
silencing with siRNA on the release and expression of
EGFR ligands, amphiregulin and TGF-α in NCI-H292




Fig. 2 Effect of P2R antagonists on MUC5AC production and release in poly(I:C)-treated NCI-H292 cells. a-c Effect of a non-selective antagonist of P2R,
suramin, on MUC5AC release in poly(I:C)-treated cells. Cells were treated with 10 μM suramin or vehicle 30 min prior to the treatment with 10 μg/ml
poly(I:C). After 24 h, whole cells were harvested, and the expression of MUC5AC was assessed with Real-time PCR (a), and the intracellular protein of
MUC5AC was assayed by ELISA (b). c Various concentrations of suramin were added 30 min before 10 μg/ml poly(I:C) treatment. After 24 h, the
supernatants were harvested and assayed for MUC5AC release by ELISA. d, e Effect of P2X7R antagonists on MUC5AC release in poly(I:C)-treated cells.
Various concentrations of a P2X7R antagonist, Brilliant Blue G (BBG), or a specific P2X7R antagonist, A438079, were added 30 min before 10 μg/ml
poly(I:C) treatment. After 24 h, supernatants were harvested and assayed for MUC5AC release. The data are expressed as the means ± SEM for three to
six separate experiments. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the values of control
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10 μM suramin significantly inhibited the release and
expression of amphiregulin (p < 0.001) (Fig. 4a and c)
and TGF-α (p < 0.001) (Fig. 4b and d). Treatment
with P2Y2R siRNA significantly suppressed the re-
lease of amphiregulin (p < 0.001) (Fig. 4e) and TGF-α
(p < 0.001) (Fig. 4f ) in poly(I:C)-treated cells.
Effect of P2R antagonist on the phosphorylation of EGFR
and ERK in poly(I:C)-treated NCI-H292 cells
Next, we investigated the effect of P2R antagonist on
EGFR and ERK1/2 phosphorylation after poly(I:C)
stimulation. Because treatment with poly(I:C) signifi-
cantly increased EGFR and ERK1/2 phosphorylation
after 4 h in our previous study [22], we evaluated the
effect of suramin 4 h after stimulation with poly(I:C).
Treatment with 10 μM suramin significantly reduced the
phosphorylation of EGFR (p < 0.001) (Fig. 5a and b) and
ERK1/2 in poly(I:C)-treated NCI-H292 cells (p < 0.01)
(Fig. 5c and d).
Involvement of extracellular ATP on MUC5AC release in
virus infected NCI-H292 cells
To confirm that the effects we observed with poly(I:C)
could be replicated with live virus in NCI-H292 cells, we
performed additional experiments using human rhino-
virus, RV 14. RV 14 infection significantly increased the
extracellular ATP and MUC5AC release (Fig. 6a and b)
(ATP; 5.38 ± 1.13 vs 13.6 ± 0.25 μM at 24 h, p < 0.01,
MUC5AC release; 1.55-fold increase at 48 h, p < 0.01).
Pre-treatment with the pannexin channel inhibitor CBX
at 10 μM reduced the amount of extracellular ATP and
partially suppressed MUC5AC release from RV 14-
infected cells (Fig. 6a and b). In addition, pre-treatment
with the P2R antagonist suramin at 10 μM significantly
reduced the release of MUC5AC from RV 14-infected
cells (Fig. 6c). Titers of RV14 in the culture supernatants
measured with endpoint methods using human embry-
onic fibroblasts [27] were 4.4 ± 0.2 Log TCID50 units/mL
(mean ± SE, n = 5) at 48 h after infection. However, no
virus was detected in the culture supernatants after
Fig. 3 Effect of P2X7R or P2Y2R silencing with siRNA on MUC5AC release in poly(I:C)-treated NCI-H292 cells. a, c Effect of P2X7R or P2Y2R silencing with
siRNA in NCI-H292 cells was evaluated by immunoblotting for 24 h after transfection. The amount of P2X7R or P2Y2R was assessed by densitometry. b, d
Effect of P2X7R or P2Y2R silencing with siRNA on the release of MUC5AC in poly(I:C)-treated cells. Cells were treated with non-targeting, P2X7R or P2Y2R
siRNA 48 h prior to the treatment with 10 μg/ml poly(I:C) or vehicle. After 24 h, supernatants were harvested and assayed for MUC5AC release by ELISA.
The data were normalized by the values to control siRNA at 0 μg/ml poly (I:C). The data are expressed as the mean ± SEM for three to four separate
experiments. P2X7 siRNA(-), P2Y2R siRNA(-) or control siRNA denotes non-targeting siRNA treatment. *p< 0.05, ***p< 0.001 compared with the values of
control. +++p< 0.001 compared with the values of control siRNA
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infection with ultraviolet (UV)-irradiated RV14 as previ-
ously reported [27] (data not shown).
Effect of pannexin channel inhibitor or P2R antagonist on
the expression of MUC5AC in poly(I:C)-treated
differentiated human bronchial epithelial cells from COPD
patients
To confirm the involvement of pannexin channel and P2R
in MUC5AC production after TLR3 stimulation in human
bronchial epithelial cells (HBECs), we used differentiated
HBECs, which mimic the in vivo features. To estimate the
MUC5AC production in differentiated HBECs, we evalu-
ated the expression of MUC5AC because the increase of
MUC5AC expression was well correlated with that of
MUC5AC release in NCI-H292 cells in our previous study
[22]. Before this examination, we evaluated the expression
of MUC5AC in differentiated HBECs between healthy
subjects and age-matched COPD patients with poly(I:C)
stimulation. After poly(I:C) stimulation, the expression of
MUC5AC in the differentiated cells from COPD patients
was significantly higher than those from healthy subjects
(p = 0.032) (Fig. 7a). The values of the expression of
MUC5AC in poly(I:C)-treated HBECs were inversely
related with forced expiratory volume in 1 s (FEV1) % pre-
dicted (r = −0.69, p < 0.05) and carbon monoxide diffusing
capacity corrected for the alveolar ventilation (DLCO/VA)
%predicted (r = −0.63, p < 0.05), but not to the smoking his-
tory (pack-years) (r = 0.56, p = 0.09) (Fig. 7b-d). Concerning
the expression of TLR3 in the differentiated HBECs after
poly(I:C) stimulation, there was no difference between the
healthy subjects and COPD patients (data not shown).
Next, we investigated the effect of pannexin channel
inhibitor, CBX or the P2R antagonist, suramin on the
poly(I:C)-potentiated expression of MUC5AC in
Fig. 4 Effect of P2R antagonist on EGFR ligand release and expression in poly(I:C)-treated NCI-H292 cells. a-d Effect of a non-selective antagonist of P2R,
suramin on the release and expression of EGFR ligands (amphiregulin and TGF-α). A 10 micromolar concentration of suramin was added 30 min before
10 μg/ml poly(I:C) treatment. After 24 h, whole cells and supernatants were harvested and assayed for the release of amphiregulin and TGF-α by ELISA and
the expression of amphiregulin and TGF-α gene by Real-time PCR. e, f Effect of P2Y2R silencing with siRNA on the release of amphiregulin and TGF-α on
poly(I:C)-treated cells. Cells were treated with P2Y2R silencing by siRNA prior to the treatment with 10 μg/ml poly(I:C). After 24 h, the supernatants were
harvested and assayed for the release of amphiregulin and TGF-α. The data are expressed as the means ± SEM for three to four separate experiments.
P2Y2R siRNA(-) siRNA denotes non-targeting siRNA treatment. **p< 0.01, ***p< 0.001 compared with the values of vehicle-treated control. +++p< 0.001
compared with the values of suramin or siRNA-treated control
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differentiated HBECs from COPD patients. Treatment
with 10 μM CBX and 10 μM and 100 μM suramin
significantly suppressed the poly(I:C)-augmented expres-
sion of MUC5AC (p < 0.001 and p < 0.01) (Fig. 7e and f).
In addition, we investigated the effect of P2X7R
antagonist on the poly(I:C)-potentiated expression of
MUC5AC in differentiated HBECs from COPD patients.
A non-selective P2X7R antagonist, BBG significantly
inhibited poly(I:C)-potentiated MUC5AC release at
50 μM (p < 0.001) (Fig. 7g), but a specific P2X7R
antagonist, A438079, did not at concentrations of up to
100 μM (Fig. 7h).
Cell viability
The effects of the inhibitors on cell viability were
assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay in NCI-H292 cells,
and with the LDH assay in differentiated HBECs. Cell
viability in the NCI-H292 cells was more than 89.7 %
after the treatment with poly(I:C), ATP, rhinovirus
infection and the inhibitors excluding CBX. Cell viability
was 78.8 % at the highest dose of CBX after poly (I:C)
treatment. In the differentiated HBECs, cell viability was
more than 75.6 % after the treatment with poly(I:C) and
the inhibitors.
Discussion
In the present study, we demonstrated that a synthetic
dsRNA analogue, poly(I:C), used as a TLR3 ligand to
mimic viral infection, increased the amount of extracel-
lular ATP and that this effect was reversed by a
pannexin channel inhibitor, carbenoxolone (CBX).
Stimulation with ATP induced the production and
release of MUC5AC in human airway epithelial cells. In
addition, we showed that pre-treatment with an inhibitor
of P2R, suramin or P2Y2R siRNA, but not P2X7R siRNA
significantly reduced the expression and release of
MUC5AC and EGFR ligands, and the phosphorylation
of EGFR and ERK in poly(I:C)-treated cells, suggesting
that extracellular ATP is involved in dsRNA-induced
MUC5AC production via P2R, especially P2Y2R (Fig. 8).
These results were replicated with human rhinovirus
and the inhibitory effects of CBX and suramin on
poly(I:C)-potentiated MUC5AC expression were con-
firmed in differentiated human epithelial cells from
COPD patients. These data suggest that viral-derived
dsRNA induces the release of ATP via pannexin channel
and that extracellular ATP is involved in the release of
MUC5AC mainly via P2Y2R in an autocrine manner
during viral-induced COPD exacerbation.
In the present study, we firstly demonstrated that
dsRNA stimulation and viral infection increased the
amounts of extracellular ATP via pannexin channel in
NCI-H292 cells. Pannexin channel has been reported to
Fig. 5 Effect of P2R antagonist on the phosphorylation of epidermal
growth factor receptor (EGFR) and extracellular signal-regulated
kinase (ERK) in poly(I:C)-treated NCI-H292 cells. Suramin was added
30 min before 10 μg/ml poly(I:C) treatment in NCI-H292 cells. After
4 h, whole cell lysates were obtained. a, b Phosphorylation of EGFR
or ERK1/2 was evaluated with immunoblotting. Band intensity was
assessed with densitometry. c, d Relative intensity was calculated by
dividing the phosphorylated EGFR or ERK1/2 band intensity by the
EGFR or ERK1/2 band intensity and the results were indicated as fold
induction over control. The data are expressed as the mean ± SEM
for three to four separate experiments. *p < 0.05, ***p < 0.001
compared with the values of vehicle-treated control
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be involved in the release of ATP from inflammatory
cells and HBECs [7, 8]. Baxter M, et al demonstrated
that cigarette smoke-bubbled medium induced the
release of ATP from HBECs via pannexin channel and
that the amount of extracellular ATP reached its peak at
3 h and reversed to the basal level at 24 h [7]. However,
in the present study, the amount of extracellular ATP in-
creased at 4 h and peaked at 16 h, which is inconsistent
with the previous study. This discrepancy might have
resulted from differences in the stimulation or in the
experimental conditions including the type of cells. An-
other possibility is that the actual starting time of ATP
release might be earlier than that of the net amount of
ATP we measured because extracellular ATP is promptly
decomposed by its metabolic enzyme, ectonucleotidases
in the extracellular space [4]. In the current study, the
inhibitory effect of CBX on the poly(I:C)-induced ATP
release was partial, suggesting that other mechanisms
might be involved in the poly(I:C)-induced ATP release,
since various pathways, such as exocytosis, specific
membrane transporters, or nonselective channels, have
been also reported to be involved in the release of
intracellular ATP to extracellular compartments [4, 29].
In the current study, it remains unclear what mecha-
nisms mediate the activation of the pannexin channel. In
previous reports, the involvement of P2X7R activation
or hypotonic stress was reported to activate the
pannexin channel [8, 9, 30]. However, the involvement
of these mechanisms in the activation of the pannexin
channel after dsRNA stimulation or RV 14 infection
remains unclear. Further studies are needed to clarify
these points.
In the present study, the potentiating effect of ATP on
the release of MUC5AC in NCI-H292 cells was
decreased at higher concentrations. This was possibly
not likely due to toxicity, because the viability of the
cells was not affected. This might be due to the existence
of negative feedback regulation of MUC5AC release
after a high dose of ATP, such as desensitization and
down regulation of P2 receptors [31, 32].
The expression of P2Y1R, P2Y2R, P2Y4R, P2Y6R and
P2XRs on the apical surface has been demonstrated in
human airway epithelial cells [33, 34]. In the present




Fig. 6 Involvement of extracellular ATP on MUC5AC release in viral-infected NCI-H292 cells. a, b Effect of a pannexin channel inhibitor, carbenoxolone
(CBX), on the release of extracellular ATP (a) and MUC5AC (b) in RV14-infected NCI-H292 cells. Cells were treated with 10 μM CBX or vehicle 1 h prior
to RV 14 infection. Cells were infected with RV 14 for 90 min and the virus was removed and replaced with medium. After 24 h or 48 h incubation,
supernatants were harvested and assayed. Supernatants were assessed for the concentration of extracellular ATP by fluorometric assay and MUC5AC
release by ELISA. c Effect of a non-selective antagonist of P2R, suramin, on MUC5AC release in RV 14-infected cells. Cells were treated with 10 μM
suramin or vehicle 30 min prior to RV 14 infection. After 48 h RV 14 infection, the supernatants were harvested and assayed for MUC5AC release by
ELISA. The data are expressed as the means ± SEM for three to four separate experiments. **p < 0.01, ***p < 0.001 compared with the values of
vehicle-treated control
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Fig. 7 Effect of pannexin channel inhibitor or P2R antagonist on the expression of MUC5AC in poly(I:C)-treated differentiated human bronchial epithelial
cells from COPD patients. a Expression of MUC5AC in poly(I:C)-treated HBECs from healthy subjects and COPD patients. HBECs were treated with 10 μg/
ml poly(I:C). After 24 h, whole cells were harvested and assayed for the expression of MUC5AC gene by Real-time PCR. The data are expressed as the
mean ± SEM of five healthy subjects or five COPD patients. b-d The relationship between the expression of MUC5AC in poly(I:C)-treated HBECs and
smoking history (pack-years), the values of forced expiratory volume in 1 s (FEV1) %predicted, or carbonmonoxide diffusing capacity corrected for alveolar
ventilation (DLCO/VA) %predicted. P-value and r were determined by Spearman’s correlation analysis in all subjects. Open circles (○) show healthy
subjects and closed squares (■) show COPD patients. r is the correlation coefficient. e, f Effect of a pannexin channel inhibitor, carbenoxolone (CBX), or a
P2R antagonist, suramin, on the expression of MUC5AC in poly(I:C)-treated HBECs from COPD patients. Cells were treated with CBX 1 h or suramin
30 min before 10 μg/ml poly(I:C) stimulation. After 24 h, whole cells were harvested and assayed for the expression of MUC5AC gene. The data is a
representative of three independent experiments with three to five samples performed by using HBECs from three COPD patients, expressed as mean ±
SEM. **p < 0.01, ***p < 0.001 compared with the values of control. g, h Effect of P2X7R antagonists on the expression of MUC5AC in poly(I:C)-treated
HBECs from COPD patients. Various concentrations of a P2X7R antagonist, BBG, or a specific P2X7R antagonist, A438079, were added 30 min before
10 μg/ml poly(I:C) treatment. After 24 h, whole cells were harvested and assayed for the expression of MUC5AC gene. The data is a representative of
three independent experiments with two to five samples performed by using HBECs from three COPD patients, expressed as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001 compared with the values of control
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P2X7R in NCI-H292 cells by western blot. A non-
selective antagonist of P2R, suramin, and a non-selective
P2X7R antagonist, Brilliant Blue G (BBG), significantly
inhibited poly(I:C)- and RV 14-potentiated MUC5AC re-
lease, but a selective P2X7R antagonist A438079 did not.
This discrepancy might have resulted from differences in
the selectivity of these antagonists. P2X7R knockdown
also did not inhibit the release of MUC5AC, suggesting
that P2X7R is not involved in the poly(I:C)-induced
MUC5AC release. However, since the efficacy of P2X7R
knockdown was partial, it remains difficult to completely
exclude the possible involvement of P2X7R. BBG is a
non-selective P2X7R antagonist and the selectivity for
human P2X7 (IC50 = 200 nM) is only 15 times higher
than that for P2XRs, especially P2X4 (IC50 = 3.2 μM)
[35]. At a 50 micromolar or higher concentration of BBG
MUC5AC inhibition was observed, which might inhibit
other P2XRs including P2X4. This suggests that there re-
mains the possible involvement of other P2XRs including
P2X4R in the poly(I:C) - and RV 14-potentiated MUC5AC
release. On the other hand, there have been several
reports showing the involvement of P2Y2R in mucin
release from secretory glands [11, 12]. In the present
study, P2Y2R knockdown significantly inhibited poly(I:C)-
augmented MUC5AC release, which is consistent with
previous studies. These data suggest that P2Y2R is mainly
involved in the dsRNA-induced MUC5AC expression and
release in NCI-H292 cells. However, the inhibitory effect
of P2Y2R knockdown on poly(I:C)-induced MUC5AC
release was only partial. This might be due to the low
efficiency of uptake of the P2Y2R siRNA into the cells. As
a limitation in this siRNA study, there remains the
possible involvement of other P2 receptors in this
mechanism because of the partial inhibitory effect of
P2Y2R knockdown on poly(I:C)-induced MUC5AC release.
EGFR-ERK signaling pathways have been reported to be
involved in poly(I:C)-induced MUC5AC expression and
release in our and others’ previous studies [21, 22]. In the
current study, we showed that the P2R antagonist suramin
and a P2Y2R siRNA significantly suppressed the release of
EGFR ligands (amphiregulin and TGF-α) in poly(I:C)-
treated NCI-H292 cells. In addition, suramin significantly
reduced the phosphorylation of EGFR and ERK1/2 in
poly(I:C)-treated NCI-H292 cells. These results suggest that
P2R, especially P2Y2R is involved in the poly(I:C)-induced
MUC5AC release upstream of the EGFR-ERK pathway.
Recently, Sham D, et al. reported that ATP activates an
NADPH oxidase homolog, DUOX1, via P2Y2R leading to
H2O2 production and that the H2O2 stimulates ADAM17,
which is also called tumor necrosis factor-α converting en-
zyme (TACE) and is responsible for the shedding of EGFR
pro-ligand and the activation of EGFR ligands [36]. This
mechanism might be involved in the poly(I:C)-induced
MUC5AC release. However, it remains unclear how P2Rs
activate the EGFR- ERK pathway after poly(I:C) stimulation;
further studies are needed to clarify this point.
The expression of MUC5AC in the airways of COPD
patients has been reported to be increased compared to
healthy subjects [37]. In the present study, we demon-
strated, for the first time as far as we know, that MUC5AC
expression in COPD patients was significantly greater
than that in healthy subjects after dsRNA stimulation in
differentiated HBECs under an air-liquid interface
condition. In the current study, the values of MUC5AC
expression in poly(I:C)-treated differentiated HBECs were
inversely related to FEV1% predicted and DLCO/VA %
Fig. 8 Schematic representation of the involvement of extracellular ATP on the release of MUC5AC induced by toll-like receptor 3 stimulation. In
this graphic summary, the involvement of TACE activated by ATP is supported by reference 36 and the involvement of EGFR-ERK pathway in
dsRNA-induced MUC5AC expression and release is also supported by reference 21 and 22. AREG: amphiregulin
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predicted, which reflects damage to the alveolar capillary
surface in patients with emphysema. This result suggests
more mucus secretion in severe COPD during viral
infections, which might lead to more frequent exacerba-
tions of COPD [14–16]. Therefore, this result may support
that COPD exacerbations become more frequent as the
severity of COPD increases [38, 39].
Concerning the mechanisms in the augmented expres-
sion of MUC5AC in COPD patients, there might be several
possibilities including the increased expression of TLR3 or
the augmented response of the EGFR-ERK signal pathway.
A previous report has shown that TLR3 expression was in-
creased in the lung tissues or HBECs from COPD patients
compared to those from non-smokers [40]. However, in the
current study, there was no difference of the expression of
TLR3 in the differentiated HBECs between healthy subjects
and COPD patients in the limited number of samples. In
our previous study, we showed that cigarette smoke, which
is a major cause of COPD, augmented the response of
EGFR-ERK signal pathway in NCI-H292 cells [22]. How-
ever, it remains unclear whether the augmentation exists in
differentiated HBECs from COPD patients; further studies
are needed to clarify this point. As a limitation of the
present study, in differentiated HBECs, it is possible that
sex differences and smoking had an influence on the results
because HBECs were derived from 4 female healthy control
subjects and 0 female COPD patients. In addition, only one
of the healthy control subjects was an ex-smoker, whereas
all 5 of the COPD patients were ex-smokers. In our
previous study, we showed that cigarette smoke augmented
poly(I:C)-stimulated MUC5AC mRNA in differentiated
HBECs [22]. However, in the present study, there was no
positive relation between smoking history and the values of
MUC5AC expression after poly(I:C) stimulation. This
discrepancy might be due to the small sample numbers.
Further studies are needed to clarify these points.
In the differentiated HBECs from COPD patients, as
well as in the NCI-H292 cells, we confirmed the inhibitory
effect of pannexin channel inhibitor (CBX), non-selective
P2R antagonist (suramin) and non-selective P2X7
antagonist (BBG), but not the selective P2X7 antagonist
(A438079), on the poly(I:C)-potentiated MUC5AC expres-
sion. Seminario-Vidal, et al. previously reported that CBX
inhibits hypotonic-induced ATP release via pannexin
channel in differentiated HBECs [41]. In addition, the in-
hibitory effect of suramin on ATP analog-induced mucin
secretion has been also shown in differentiated HBECs
[12]. These results support the possible involvement of
extracellular ATP in dsRNA-induced MUC5AC expres-
sion via P2R in differentiated HBECs.
Conclusions
We demonstrated that dsRNA and viral infection induce
the release of ATP via pannexin channel and that
extracellular ATP is involved in the expression and release
of MUC5AC via P2R, especially P2Y2R, in NCI-H292 cells
and differentiated HBECs from COPD patients. These
data suggest the involvement of extracellular ATP in vir-
al-derived dsRNA-induced mucin expression and release
mainly via P2Y2R in an autocrine manner during viral-
induced COPD exacerbation. Modulation of this pathway
could be a therapeutic target for viral-induced mucus hy-
persecretion in COPD exacerbations.
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